Instructions for Aceclagin (aceclofenac) pills
Pharmaco Therapeutic Group
Storage conditions:
The drug Aceclagin should be stored in a place inaccessible to children at a temperature not higher than 30 ° C.
Shelf life
Shelf life is 2 years. Do not apply after the expiration date specified on the package.
Pharmacological action Aceclagin (aceclofenac) pills:
Aceclofenac has an anti-inflammatory, analgesic, antipyretic effect. It inhibits the synthesis of prostaglandins and thus affects the pathogenesis of inflammation, pain and fever. In rheumatic diseases, the anti-inflammatory and analgesic effect of aceclofenac contributes to a significant decrease in the severity of pain, morning stiffness, swelling of the joints, which improves the functional state of the patient.
Indications Aceclagin (aceclofenac) pills:
suppression of inflammation and pain syndrome in lumbago, toothache, shoulder periarthritis, rheumatic damage to soft tissues;
for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis;
Symptomatic therapy, reduction of pain and inflammation at the time of use, does not affect disease progression.
dysmenorrhea.
Method of use, course and dosage Aceclagin (aceclofenac) pills:
The drug Aceclagin is taken inside. Tablets should be ingested as a whole, drinking enough water.
The recommended daily dose for adults is 200 mg with a single dose (1 table/day).
Overdose:
There is no data on the overdose of aceclophenac in humans.
Possible symptoms include: nausea, vomiting, stomach pain, dizziness, headache, hyperventilation phenomena with increased convulsion readiness.
Treatment: stomach washing, activated carbon intake, symptomatic therapy;
Forced diuresis, hemodialysis is not effective enough.
Drug Interaction Aceclagin (aceclofenac) pills:
Except for simultaneous application with varfarin, no drug Aceclagin interaction studies were conducted.
Aceclophenac is metabolized by the isoferment CYP2C9; In vitro data show that aceclophenac can be an inhibitor of this enzyme. Thus, the risk of pharmacokinetic interaction is possible when simultaneously taken with phenythine, cymethydin, tolubutamide, phenyl butazon, amyodarone, myconazole and sulfaphenazol. As with other NPAs, the risk of pharmacokinetic interaction with other drugs Aceclagin that are derived from the body by active kidney secretion, such as metarexate and lithium preparations, is increasing. Aceclofenac is almost completely associated with albumin of the blood plasma and therefore there is an opportunity to interact by the type of crowding with other preparations associated with proteins.
Below is a class-specific information for the NPA.
Metotrexate. NPAs inge the sewer secretion of the metotrexate; Moreover, there may be a small metabolic interaction, which leads to a reduction in the clergy of metotrexate. Therefore, the use of high-dose metarexate should be avoided with the use of NRMM.
Lithium and digoxine drugs Aceclagin. Some NPAs ingibate the renal clearance of lithium and digoxine, leading to an increase in the concentration of both substances in the blood serum. Co-application should be avoided if lithium and digoxine concentrations are not frequently controlled.
Anticoagulants. The NPAP inhibates the aggregation of platelets and damages the mucous membrane of the LCT, which can lead to increased anticoagulants and increase the risk of gastrointestinal hemorrhage while taking anticoagulants. Co-use of aceclophenacs and oral anticoagulants of the kumarine group, ticlopidine and trombolitis should be avoided unless careful monitoring of the patient's condition is carried out.
Anti-aggregation and selective serotonin re-takeoff inhibitors (SSRIs), when used in conjunction with the NPA, can increase the risk of gastrointestinal bleeding.
Ciclosporine, Tacrolimus. When simultaneously taking NPAs with cyclosporin or takrolimus, the risk of increased petrotoxicity due to reduced formation of kidney prostacycline should be taken into account.
Therefore, when taking a kidney, carefully monitor the performance of the kidney.
Other NPAs. If you take acetylsalicinic acid or other NPAs at the same time, the occurrence of side effects may increase, so care should be taken.
GKS. The risk of anthrax or gastrointestinal bleeding is increasing.
Diuretics. Aceclofenac, like other NPAVs, can inhibit diuretic activity, reduce the diuretic effect of furosemid and bumetanide and the antihypertensive effect of thiazid. Simultaneous intake with potash-saving diuretics can increase potassium content in the blood serum. When simultaneously used with potash-saving diuretics, potassium control in blood serum is necessary. Aceklofenak did not influence Ad's control in joint application with bendrofluasis, although interaction with other diuretics cannot be excluded.
Hypotensive drugs Aceclagin. NPAs can also reduce the effect of hypotensive drugs Aceclagin. Co-acceptance of APF inhibitors or anthagonists of angiotenzin II receptors and NPAP receptors may result in kidney failure. The risk of acute kidney failure, which is usually reversible, may increase in some patients with kidney impairment, such as the elderly or dehydration. Therefore, caution should be exercised when sharing with NPAs. Patients must consume the necessary fluid and be monitored (kidney function monitoring at the start of the joint application and periodically during treatment).
Hypoglikemics. Clinical studies show that diclofenac can be used in conjunction with oral hypoglycemics without affecting their clinical effect. However, there are some reports of hypoglycemic and hyperglycemic effects of the drug Aceclagin. Thus, when taking aceclophenac, it is necessary to correct doses of drugs that may cause hypoglycemia.
Zidovudin. When simultaneously taking NPAs and zidovudine, the risk of hematological toxicity increases. There is evidence of an increase in the risk of hemarthrosis and hematoma in HIV-positive (human immunodeficiency virus) patients with hemophilia receiving zidovudin and ibuprofen.
Use in pregnancy and breastfeeding
Pregnancy
The use of the drug Aceclagin is contraindicated during pregnancy. Information on the use of aceclophenac in pregnancy is not available. The oppression of prostaglandin synthesis may adversely affect the course of pregnancy and/or the development of the embryo/fetus.
During the III trimester of pregnancy all inhibitors of prostaglandin synthesis:
Having cardiopulmonary toxicity, can cause premature closure of the botalite flow with the development of pulmonary hypertension;
may cause a fetal kidney function impairment, which may progress to kidney failure in combination with multi-thickness.
In late pregnancy:
The drug Aceclagin can affect the duration of the bleeding due to an anti-aggregative effect, which can develop even after application in very low doses;
The drug Aceclagin can suppress the contraction of the uterus, resulting in delayed childbirth or prolonged childbirth.
Breastfeeding period
The drug Aceclagin should not be taken while breastfeeding. Data on the allocation of aceclophenac with female milk are not available. In pre-clinical studies, when the radioactive 14C-aceclophenac was introduced, there was no noticeable transfer of radioactivity into milk.
Side Action:
The following are undesirable phenomena reported in clinical trials and post-marketing surveillance.
The frequency of unwanted phenomena is classified as follows: very often (≥1/10); frequently (≥1/100 to <1/10); infrequently (≥1/1000 to <1/100), rarely (≥1/10000 to <1/1000), very rarely (<1/10000).
On the side of the blood-producing system: rarely anemia; Very rarely - oppression of bone marrow function, granulocytopenia, thrombocytopenia, neuropenia, hemolytic anemia.
From the immune system: rarely - anaphylactic reactions, including shock, hypersensitivity.
From metabolism and nutrition: Very rarely - hyperkalemia, body mass increase.
From the psyche: Very rarely - depression, unusual (atypical) dreams, insomnia.
On the side of the nervous system: often - dizziness; Very rarely - pastesia, tremor, sleepiness, headache, disgevsia (perversion of taste).
From the viewpoint: rarely is a visual impairment.
From the organ of the hearing and maze: Very rarely - vertically, noise in the ears.
On the side of the cardiovascular system: seldom - heart failure, AD rise, blood pressure deterioration; It is very rare - frequent heartbeat, skin hyperemia, "tides" (short-term heat sensation accompanied by sweat), vasculitis.
From the respiratory system: rarely - breathing; Very rarely - bronchospasm.
From the digestive system: Often - dyspepsia, abdominal pain, nausea, diarrhea; Infrequently - meteorism, gastritis, constipation, vomiting, mucous membranes of the mouth; seldom melena, mucous ultrasound ultrasound ultrasound ultrasound ultrasound, hemorrhagic diarrhagic hemp; very rarely - dental, vomiting blood, intestinal prostate, deterioration of the flow of Crohn's disease and ulcer colitis, pancreatitis.
On the side of the liver and bile-producing tract: Often - increase of liver enzyme activity; Very rarely - liver damage (including hepatitis), increase of activity of the SFF.
On the skin and subcutaneous fiber side: Infrequently - itching, rash, dermatitis, nettles; rarely angionevrotic swelling; very seldom - purpura, eczema, heavy reactions from the skin and mucous membranes (including Stevens-Johnson syndrome and toxic epidermal necrolysis). In some cases, serious skin infections and soft tissue infections were observed when NPAs were administered during the disease of wind smallpox.
On the side of the urinary system: Infrequently - increased urine and creatin concentrations in blood serum; Very rarely - nephrotic syndrome, kidney failure.
Others: Very rarely - swelling, increased fatigue, muscle spasms of the lower limbs.
If a patient has noted a deterioration of any of the listed undesirable phenomena or an undesirable phenomenon not specified in this instruction, he or she should contact the doctor in charge.
Use in disorders of kidney function
The drug Aceclagin is contraindicated for severe renal failure (QC < 30 ml/min), progressive kidney diseases.
With caution: a history of kidney disease, chronic renal failure, QC less than 60 ml/min.
Use in impaired liver function
The drug Aceclagin is contraindicated for severe liver failure or liver diseases in the active stage.
With caution: a history of liver disease, chronic liver failure.
Use in children
Contraindicated use under the age of 18 years.
Nosology (ICD codes)
Other refined changes in teeth and their support apparatus (including toothache)
M05
Seropositive rheumatoid arthritis
M15
Polyarthrosis
M25.5
Joint pain
M42
Osteochondrosis of the spine
M45
Ankylosing spondylitis
M47
Spondilez
M54.1
Radikulopatiya
M54.3
Sciatica
M54.4
Lumbago with ischias
Shoulder Adhesive Capsule
Rheumatism unspecified
Primary dysmenorrhea
Secondary dysmenorrhea
Acute pain
Other persistent pain (chronic)
